<DOC>
	<DOCNO>NCT00730730</DOCNO>
	<brief_summary>The purpose study show new delivery system modify stent safe treating occlude iliac artery patient peripheral vascular disease . The modified Complete SE delivery system hypothesize assist physician accurate stent placement reduce likelihood stent 'jumping ' see use many self-expanding stent system .</brief_summary>
	<brief_title>The Complete® Self-Expanding Stent Stent Delivery System Registry</brief_title>
	<detailed_description>The study conduct collect 30-day safety data stent delivery system subject enrol study ( minimum 50 subject enrol ) well long-term 9-month safety efficacy data subject enrol ( minimum 10 subject enrol study 120mm length stent implant ) .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>The lesion ( ) either denovo restenotic nature , locate either common iliac artery external iliac artery &gt; 50 % stenosed Target vessel reference diameter ≥ 4.5 mm ≤ 9.5 accommodate stent diameter 6.0 10.0mm Subject either asymptomatic lesion stenosis ≥70 % symptomatic lesion stenosis ≥50 % Ankle Brachial Index ( ABI ) &lt; 0.90 Toe Brachial Index ( TBI ) &lt; 0.80 abnormal Pulse Volume Recording ( PVR ) ; Total lesion length &lt; 110 mm ; Excessive Peripheral Vascular Disease ( PVD ) , unresolved fresh thrombus tortuosity target lesion/vessel heavily calcify ; Tissue loss extremity : category 5 6 Rutherford scale ; Target lesion previous stent , within prosthetic vascular bypass graft within 1 cm graft anastomosis ; Target lesion within aneurysm associate aneurysm vessel segment proximal distal target lesion ; Lesion require treatment nonstandard device associate Percutaneous Transluminal Angioplasty ( PTA ) prior stent placement ; Inadequate distal runoff ; Planned interventional procedure vascular surgery target vessel within 30 day pre postindex iliac procedure ; History bleeding diatheses coagulopathy refuse blood transfusion ; Platelet count &lt; 50,000 cells/mm3 &gt; 700,000 cells/mm3 , White Blood Count ( WBC ) &lt; 3,000 cells/mm3 ; Creatinine &gt; 2.0 mg/dl ; Participation another investigational device drug study complete primary endpoint ( ) followup phase study least 30 day prior enrollment trial subject previously enrol Registry ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Iliac Artery , Peripheral Vascular Disease ( PVD )</keyword>
</DOC>